New HIV drug combo for kids shows promise in african study
NCT ID NCT05993767
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tested whether a new combination of three HIV medicines (dolutegravir, emtricitabine, and tenofovir alafenamide) at a special dose works well and is safe for children living with HIV in Africa. 53 children aged 28 days to 10 years took part. The goal is to create a single, easy-to-take tablet that dissolves in water, making it simpler for children to get the right dose every day.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine Children's Foundation
Kampala, Uganda
-
Joint Research Centre
Kampala, Uganda
-
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Conditions
Explore the condition pages connected to this study.